Načítá se...
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma
We report a single institution phase II study of gemcitabine 1200 mg m(−2) i.v. on days 1 and 8 and capecitabine 1300 mg m(−2) twice daily on days 1–14 of each 3-week cycle in patients with metastatic renal carcinoma. Patients had a WHO performance status of 0, 1 or 2. Of the 21 enrolled patients, 1...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
2004
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2410054/ https://ncbi.nlm.nih.gov/pubmed/15505625 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602209 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|